Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
NCT01446016
Completed
The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therapy. The investigators want to see the response of breast cancer cell when treated with Chloroquine used in combination with chemotherapy. Chemotherapy is an anti-cancer drug that is given through your vein. The chemotherapy used in this study is either Ta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Houston Methodist Hospital Cancer Center, Houston, Texas +2 locations
Conditions: Breast Neoplasms, Breast Cancer
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01647828
Completed
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/19/2023
Locations: Western Regional Medical Center, Inc., Goodyear, Arizona +25 locations
Conditions: Stage IV Pancreatic Cancer
Register for Updates
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
NCT03301350
Completed
This is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast cancer in neoadjuvant settings.
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
01/09/2023
Locations: Swedish American Hospital, Rockford, Illinois +5 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
NCT03398655
Completed
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/08/2023
Locations: UAB Division of GYN Oncology, Birmingham, Alabama +93 locations
Conditions: Recurrent Platinum Resistant Ovarian Cancer
Register for Updates
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
NCT02581982
Completed
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2023
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Transitional Cell Carcinoma
Register for Updates
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT04249167
Withdrawn
This early phase I trial studies the side effects and feasibility of cryoablation, atezolizumab, and nab-paclitaxel in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the canc... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/05/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT03214250
Completed
The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2022
Locations: University of California, Los Angeles, Los Angeles, California +6 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
NCT02873598
Completed
This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy (FOLFIRINOX or gemcitabine and nab-paclitaxel).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/15/2022
Locations: University of Colorado, Aurora, Colorado
Conditions: Pancreatic Cancer
Register for Updates
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
NCT03136055
Completed
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2022
Locations: University of California, San Francisco, San Francisco, California +2 locations
Conditions: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Register for Updates
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
NCT05233696
Withdrawn
Patients with locally advanced unresectable or metastatic programmed cell death ligand (PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to one-four sites of metastasis amenable to radiation (sites of disease to be selected at the discretion of the treating radiation oncologist) followed by initiation of systemic therapy with pembrolizumab plus nab-paclitaxel/paclitaxel. Patients will be treated with pembrolizumab plus nab-paclitaxel/paclitaxel within 7 days of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/02/2022
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer, PD-L1 Gene Mutation
Register for Updates
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
NCT00017407
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without ISIS 3521. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel with or without ISIS 3521 in treating patients who have stage IIIB or stage IV non-small cel... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/01/2022
Locations: ISIS Pharmaceuticals, Inc., Carlsbad, California +1 locations
Conditions: Lung Cancer
Register for Updates
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
NCT04132817
Completed
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting multiple, distinct combination regimens that modulate several immune and non-immune mechanisms by escalating the number of therapies administere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: Local Institution, Los Angeles, California +7 locations
Conditions: Breast Cancer
Register for Updates